Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.
Curr Oncol Rep
; 24(11): 1387-1400, 2022 11.
Article
em En
| MEDLINE
| ID: mdl-35653050
PURPOSE OF REVIEW: Treatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous disease biology, and a rapidly evolving treatment landscape. Here, we highlight the importance of determining fitness, review the latest therapeutic developments, and discuss clinical scenarios to provide guidance on individualized treatment for older AML patients. RECENT FINDINGS: Several factors, like age, performance status, and comorbidities, play a role in fitness and are associated with outcome. Comorbidity scoring systems and geriatric assessments are tools to help physicians select the most appropriate treatment for each patient. The addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and enhanced formulas of existing drugs like CPX-351 and oral azacitidine have improved responses and outcomes. New drugs and combination therapies have increased the therapeutic options for elderly AML patients but determination of fitness and disease biology is essential to select patient-tailored treatments.
Palavras-chave
Acute myeloid leukemia; Azacitidine; CC-486; CPX-351; Decitabine; Elderly; Enasidenib; FTL3 inhibitors; Fitness; Gemutuzumab ozogamicin; Gilteritinib; Glasdegib; Hematopoietic stem cell transplantation; Hypomethylating agents; IDH inhibitors; Intensive chemotherapy; Ivosidenib; Midostaurin; Targeted therapy; Treatment; Venetoclax; Vyxeos
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
Tipo de estudo:
Guideline
Limite:
Aged
/
Humans
Idioma:
En
Revista:
Curr Oncol Rep
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Holanda